Report an error   
Advanced Search

First-line treatment of metastatic breast cancer with Taxotere and doxorubicin among Filipino women: A pilot study.


Roberto A. Bolinas Jr.,
Gloria Cristal-Luna,
Emerlinda Nacino-Batac

Related Institution

Section of Surgical Oncology, Cancer Institute - St. Luke's Medical Center

Publication Information

Publication Type
Publication Sub Type
Journal Article, Original
Philippine Journal of Oncology
Publication Date
June- 2002


PURPOSE: To describe the outcome of treatment with doxorubicin 50 mg/m2 and docetaxel 60 mg/m2 in Filipino patients with advanced breast carcinoma in terms of response rate, survival, clinical benefit and toxicity

PATIENTS AND METHODS: Thirty-seven (37) advanced breast cancer patients aged 18-72 years old with performance status (WHO) 0-2, and adequate bone marrow, renal, liver and cardiac function were enrolled in the study. Doxorubicin was given at 50 mg/m2 slow IV push over 15 minutes followed one hour after by Taxotere 60 mg/m2 as one hour infusion. Decilone 8 mg premedication on Day-1, 1, 2 was given. The mean age was 46 years. Fifty-one percent were pre-menopausal and 50 percent had visceral metastasis. Hormonal receptor assay was done in 30 percent of patients.

RESULTS: Thirty-one patients were evaluable for response. There were 78 percent responders among the valuable patients. Four patients (13 percent) had complete response and twenty-one (65 percent) patients had partial response. Responses were noted as early at the 3rd cycle of chemotherapy in twenty-three (72 percent) patients. Febrile neutropenia occurred in 10.7 percent cycles with no toxic deaths. Diarrhea occurred in 17 percent cycles but was deemed serious in 8 percent of cases. Symptomatic pericardial effusion, which was cytology negative, occurred in one (1) patient. There was no CHF reported. The median duration of response has not been reached at greater than 10.2 months. Median survival has not yet been reached.

CONCLUSION: The combination of doxorubicin 50 mg/ml and Taxotere 60 mg/m2 is active and well-tolerated as first-line in Filipino women with advanced breast cancer. (Author)


1. McPherson K, , Stoel CM , , Dixon JM, . "Breast Cancerepidemiology, risk factors and genetics. " Med J 309, 1003-1006., 1994
2. Lecciones JA, . Crista I-Luna GR (Editors). The Philippine Handbook of Clinical Oncology . 1997. 79-93.
3. Harris JR, , Lippman ME, , Veronesi U, et al, . "Breast cancer (third of three Parts). " N Engl J Med 327, 473-480, 1992
4. Mourisden HT, . "Systemic therapy of advanced breast cancer. " Drugs 44, 17-28, 1992
5. Leonard RCF, , Rodger A, , Dixon J, . "ABC of breast diseases. Metastatic breast cancer. " Br Med J 309, 1501-1504, 1994
6. Branabilla C, , Rossi A, , Bonfante V, et al, . "hase II study of doxorubicin versus epirubicin in advanced breast cancer. " Cancer Treat Rep 70, 261-266, 1988
7. Carmo-Pereira J, , Costa FO, , Henriquez E, et al, . "A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. " Br Med J 56, 471-473, 1987
8. "Rhone-Poulence Rorer. Data on File International Registration Department, Antony France " , 1994
9. Ringell, , Horwitz SB, . "Studies with RP 56976 (Taxotere): A Semisynthetic analogue of Taxol. " J Natl Cancer Inst 83, 288-291, 1981
10. Manfredi JJ, , Herwitz SB, . "Taxol, an anti-mitotic agent with a new mechanism of action. " Pharmacol Ther 26, 83-125, 1984
11. Skeel RT, . (Ed):Handbook of Cancer Chemotherapy 5th Edition. x. Lippincot Williams and Wilkins 199, 100.
12. Dieras V, . "Docetaxel in combination with doxorubicin: A phase I dose-finding study. " Oncology 11(Suppl 6): 17-20, 1997
13. Sperano JA, , Malik UR, , Wolffe A, . "Phase I trial of liposomal doxorubicin (Doxil) and docetaxel in patients with advanced breast cancer." Proc Am Soc Clin Oncol : 17, 176a. (abs, 1998

Physical Location

LocationLocation CodeAvailable FormatAvailability
Philippine Council for Health Research and Development Box No. 61 Fulltext Print Format
Philippine Council for Health Research and Development Fulltext pdf (Request Document)

©2022 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date